-
Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for gliomas Brain Tumor Pathol. (IF 3.3) Pub Date : 2024-02-08
Abstract A prompt and reliable molecular diagnosis for brain tumors has become crucial in precision medicine. While Comprehensive Genomic Profiling (CGP) has become feasible, there remains room for enhancement in brain tumor diagnosis due to the partial lack of essential genes and limitations in broad copy number analysis. In addition, the long turnaround time of commercially available CGPs poses an
-
Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment Brain Tumor Pathol. (IF 3.3) Pub Date : 2024-01-31
Abstract Oligodendrogliomas characterized and defined by 1p/19q co-deletion are slowly growing tumors showing better prognosis than astrocytomas. TP53 mutation is rare in oligodendrogliomas while the vast majority of astrocytomas harbor the mutation, making TP53 mutation mutually exclusive with 1p/19q codeletion in lower grade gliomas virtually. We report a case of 51-year-old woman with a left fronto-temporal
-
Pediatric diffuse glioma with EP300::BCOR fusion manifesting as low-grade epilepsy-associated neuroepithelial tumor: a case presentation Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-12-22 Satoshi Nakata, Yasuhito Arai, Kohei Fukuoka, Takahiro Shirakura, Ayako Yamazaki, Sho Osawa, Natsuko Hama, Tatsuhiro Shibata, Takaaki Miyagishima, Keishi Horiguchi, Masahiko Tosaka, Hideaki Yokoo, Yuhei Yoshimoto, Sumihito Nobusawa
-
A rare case of primary central nervous system histiocytic sarcoma harboring a novel ARHGAP45::BRAF fusion: a case report and literature review Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-12-15 Luyi Zhang, Gang Zhang, Han Zheng, Bin Jiang, Yongzhi Ju, Qianqian Duan, Lu An, Hangyu Shi
-
FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-12-14
Abstract Deletion of CDKN2A occurs in 50% of glioblastomas (GBM), and IFNA locus deletion in 25%. These genes reside closely on chromosome 9. We investigated whether CDKN2A and IFNA were co-deleted within the same heterogeneous tumour and their prognostic implications. We assessed CDKN2A and IFNA14 deletions in 45 glioma samples using an in-house three-colour FISH probe. We examined the correlation
-
Primary papillary epithelial tumor of the sella: a case report of an emerging tumor type Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-12-13 S. Rima, Shilpa Rao, Pulak Nigam, Rajneesh Kacchara
-
Touch imprint cytology is useful for the intraoperative pathological diagnosis of PitNETs’ surgical margins Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-10-06 Noriaki Tanabe, Naoko Inoshita, Atsushi Ishida, Masataka Kato, Haruko Yoshimoto, Hideki Shiramizu, Hidetaka Suga, Toru Tateno, Kenichi Ohashi, Shozo Yamada
-
Intraventricular central neurocytoma molecularly defined as extraventricular neurocytoma: a case representing the discrepancy between clinicopathological and molecular classifications Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-09-11 Daisuke Sato, Hirokazu Takami, Shunsaku Takayanagi, Masako Ikemura, Reiko Matsuura, Shota Tanaka, Nobuhito Saito
-
Integrated analysis of multiple methods reveals characteristics of the immune microenvironment in medulloblastoma Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-08-09 Kaiyu Fan, Yifan Wei, Yunwei Ou, Jian Gong
-
Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype: case series of a new entity Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-08-10 Katja Bender, Johannes Kahn, Eilís Perez, Felix Ehret, Siyer Roohani, David Capper, Simone Schmid, David Kaul
-
Spontaneous malignant transformation of trigeminal schwannoma: consideration of responsible gene alterations for tumorigenesis—a case report Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-07-29 Natsuki Ogasawara, Shinji Yamashita, Koji Yamasaki, Tomoki Kawano, Tomohiro Kawano, Junichiro Muta, Fumitaka Matsumoto, Takashi Watanabe, Hajime Ohta, Kiyotaka Yokogami, Tsuyoshi Fukushima, Yuichiro Sato, Hideo Takeshima
-
A clinicopathological analysis of supratentorial ependymoma, ZFTA fusion-positive: utility of immunohistochemical detection of CDKN2A alterations and characteristics of the immune microenvironment Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-06-16 Naohito Hashimoto, Tomonari Suzuki, Keisuke Ishizawa, Sumihito Nobusawa, Hideaki Yokoo, Ryo Nishikawa, Masanori Yasuda, Atsushi Sasaki
-
α-SMA positive vascular mural cells suppress cyst formation in hemangioblastoma Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-06-05 Maki Sakaguchi, Riho Nakajima, Toshiya Ichinose, Shingo Tanaka, Ryouken Kimura, Hemragul Sabit, Satoko Nakada, Mitsutoshi Nakada
-
IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-05-22 Satoshi Nakasu, Shoichi Deguchi, Yoko Nakasu
-
Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-04-22 Naoki Shinojima, Kazutaka Ozono, Haruaki Yamamoto, Sakiko Abe, Rumi Sasaki, Yusuke Tomita, Azusa Kai, Ryosuke Mori, Takahiro Yamamoto, Ken Uekawa, Hirotaka Matsui, Kisato Nosaka, Hiroaki Matsuzaki, Yoshihiro Komohara, Yoshiki Mikami, Akitake Mukasa
-
Immunohistochemical and ultrastructural review of six cases previously diagnosed as null cell PitNETs Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-04-18 Naoko Inoshita, Toyoki Yoshimoto, Yutaka Takazawa, Noriaki Fukuhara, Mitsuo Okada, Hiroshi Nishioka, Shozo Yamada
-
Spatial metabolic heterogeneity of oligodendrogliomas at single-cell resolution Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-04-11 Sai Batchu, Michael Joseph Diaz, Giona Kleinberg, Brandon Lucke-Wold
-
An enduring debate on gliomatosis cerebri Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-04-06 Jiro Akimoto
-
Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-04-01 Yoshihiro Otani, Kaishi Satomi, Yasuki Suruga, Joji Ishida, Kentaro Fujii, Koichi Ichimura, Isao Date
-
Preface for Brain Tumor Pathology vol.40 issue 2 Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-03-31 Atsushi Sasaki
-
Impact of tumor markers on diagnosis, treatment and prognosis in CNS germ cell tumors: correlations with clinical practice and histopathology Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-03-30 Hirokazu Takami, Christopher S. Graffeo, Avital Perry, Caterina Giannini, Yoichi Nakazato, Nobuhito Saito, Masao Matsutani, Ryo Nishikawa, David J. Daniels, Koichi Ichimura
-
Easy-to-use machine learning system for the prediction of IDH mutation and 1p/19q codeletion using MRI images of adult-type diffuse gliomas Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-03-29 Tomohide Nishikawa, Fumiharu Ohka, Kosuke Aoki, Hiromichi Suzuki, Kazuya Motomura, Junya Yamaguchi, Sachi Maeda, Yuji Kibe, Hiroki Shimizu, Atsushi Natsume, Hideki Innan, Ryuta Saito
-
Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-03-29 Kazuya Motomura, Yuji Kibe, Fumiharu Ohka, Kosuke Aoki, Junya Yamaguchi, Ryuta Saito
-
Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-03-09 Ryota Tamura, Akio Iwanami, Kentaro Ohara, Masaaki Nishimoto, Eriel Sandika Pareira, Tomoru Miwa, Naoko Tsuzaki, Yuki Kuranari, Yukina Morimoto, Masahiro Toda, Hideyuki Okano, Masaya Nakamura, Kazunari Yoshida, Hikaru Sasaki
-
High-grade neuroepithelial tumor with EP300::BCOR fusion and negative BCOR immunohistochemical expression: a case report Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-02-22 Hirokazu Sugino, Kaishi Satomi, Taisuke Mori, Yuuki Mukai, Mai Honda-Kitahara, Yuko Matsushita, Koichi Ichimura, Yoshitaka Narita, Akihiko Yoshida
-
Liquid biomarkers in glioma Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-02-17 Sho Tamai, Toshiya Ichinose, Mitsutoshi Nakada
An ideal biomarker must meet several parameters to enable its successful adoption; however, the nature of glioma makes it challenging to discover valuable biomarkers. While biomarkers require simplicity for clinical implementation, anatomical features and the complexity of the brain make it challenging to perform histological examination. Therefore, compared to biomarkers from general histological
-
Utility of real-time polymerase chain reaction for the assessment of CDKN2A homozygous deletion in adult-type IDH-mutant astrocytoma Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-02-14 Yuzaburo Shimizu, Mario Suzuki, Osamu Akiyama, Ikuko Ogino, Yuko Matsushita, Kaishi Satomi, Shunsuke Yanagisawa, Makoto Ohno, Masamichi Takahashi, Yasuji Miyakita, Yoshitaka Narita, Koichi Ichimura, Akihide Kondo
-
Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-12-26 Hirokazu Takami, Akitake Mukasa, Shunsaku Takayanagi, Tsukasa Koike, Reiko Matsuura, Masako Ikemura, Tetsuo Ushiku, Gakushi Yoshikawa, Junji Shibahara, Shota Tanaka, Nobuhito Saito
-
Correlation of MTAP immunohistochemical deficiency with CDKN2A homozygous deletion and clinicopathological features in pleomorphic xanthoastrocytoma Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-12-22 Lei Lou, Jiajun Li, Manman Qin, Xiaoxi Tian, Wenli Guo, Yuehong Li
-
Update of the 2021 WHO classification of tumors of the central nervous system: adult diffuse gliomas. Brain Tumor Pathol. (IF 3.3) Pub Date : 2023-01-01 Takashi Komori
-
Three-dimensional visualization of human brain tumors using the CUBIC technique Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-11-12 Yangyang Xu, Qi He, Mengqi Wang, Yang Wu, Yifeng Shi, Wei Wang, Jie Zhang
-
PBRM1 and BAP1: novel genetic mutations in malignant transformation of craniopharyngioma—a case report Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-11-11 Mitsuru Tamura, Kiyotaka Yokogami, Takashi Watanabe, Tomoki Kawano, Junichiro Muta, Shinji Yamashita, Nobuyuki Oguri, Yuichiro Sato, Hideo Takeshima
-
An extracranial CNS presentation of the emerging “intracranial” mesenchymal tumor, FET: CREB-fusion positive Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-09-15 Arnault Tauziède-Espariat, Gaëlle Pierron, Delphine Guillemot, Chiara Benevello, Johan Pallud, Joseph Benzakoun, Lauren Hasty, Alice Métais, Fabrice Chrétien, Pascale Varlet
-
Clinical application of a highly sensitive digital PCR assay to detect a small fraction of IDH1 R132H-mutant alleles in diffuse gliomas Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-07-29 Kaishi Satomi, Akihiko Yoshida, Yuko Matsushita, Hirokazu Sugino, Kenji Fujimoto, Mai Honda-Kitahara, Masamichi Takahashi, Makoto Ohno, Yasuji Miyakita, Yoshitaka Narita, Yasushi Yatabe, Junji Shibahara, Koichi Ichimura
-
Whole-genome sequencing analysis of an atypical teratoid/rhabdoid tumor in a patient with Phelan–McDermid syndrome: a case report and systematic review Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-06-24 Haruki Yamashita, Yoshiki Arakawa, Yukinori Terada, Yasuhide Takeuchi, Yohei Mineharu, Sosuke Sumiyoshi, Shinya Tokunaga, Kohei Nakajima, Naoko Kawabata, Kuniaki Tanaka, Masahiro Tanji, Katsutsugu Umeda, Sachiko Minamiguchi, Seishi Ogawa, Hironori Haga, Junko Takita, Susumu Miyamoto
-
Aggressive nonfunctioning pituitary neuroendocrine tumors Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-06-20 Sérgio Portovedo, Leonardo Vieira Neto, Paula Soares, Denise Pires de Carvalho, Christina Maeda Takiya, Leandro Miranda-Alves
-
Loss of H3K27me3 in WHO grade 3 meningioma Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-06-09 Andrea Daniela Maier, Christian Beltoft Brøchner, Christian Mirian, Jeppe Haslund-Vinding, Jiri Bartek, Tomas J. Ekström, Frantz Rom Poulsen, David Scheie, Tiit Mathiesen
-
A primary DICER1-sarcoma with KRAS and TP53 mutations in a child with suspected ECCL Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-06-06 Kaiyun Yang, Justin Wang, Nisha Kanwar, Anita Villani, Olufemi Ajani, Adam Fleming, Vikas Patil, Yasin Mamatjan, Qingxia Wei, David Malkin, Adam Shlien, Gelareh Zadeh, John Provias
-
Revisiting the definition of glioma recurrence based on a phylogenetic investigation of primary and re-emerging tumor samples: a case report Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-06-06 Toru Umehara, Hideyuki Arita, Fuyuki Miya, Takamune Achiha, Tomoko Shofuda, Ema Yoshioka, Daisuke Kanematsu, Tomoyoshi Nakagawa, Manabu Kinoshita, Naoki Kagawa, Yasunori Fujimoto, Naoya Hashimoto, Hiroki Kiyokawa, Eiichi Morii, Tatsuhiko Tsunoda, Yonehiro Kanemura, Haruhiko Kishima
-
A novel YAP1-MAML2 fusion in an adult supra-tentorial ependymoma, YAP1-fused Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-05-22 Arnault Tauziède-Espariat, Aurore Siegfried, Yvan Nicaise, Dominique Figarella-Branger, Romain Appay, Suhan Senova, Dorian Bochaton, Lauren Hasty, Anna Martin, Fabrice Chrétien, Alice Métais, Pascale Varlet, Emmanuelle Uro-Coste
-
Diffusely infiltrating glioma with CREBBP–BCORL1 fusion showing overexpression of not only BCORL1 but BCOR: A case report Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-05-21 Ayako Yamazaki, Yasuhito Arai, Kohei Fukuoka, Yoshiko Nakano, Natsuko Hama, Satoshi Nakata, Keishi Makino, Jun-Ichiro Kuroda, Naoki Shinojima, Akitake Mukasa, Yoshiki Mikami, Koichi Ichimura, Tatsuhiro Shibata, Hideaki Yokoo, Sumihito Nobusawa
-
Ribosomal proteins induce stem cell-like characteristics in glioma cells as an “extra-ribosomal function” Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-05-05 Takuichiro Hide, Ichiyo Shibahara, Madoka Inukai, Ryota Shigeeda, Yuki Shirakawa, Hirofumi Jono, Naoki Shinojima, Akitake Mukasa, Toshihiro Kumabe
-
T2-fluid-attenuated inversion recovery mismatch sign in lower grade gliomas: correlation with pathological and molecular findings Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-04-28 Shinji Yamashita, Hideo Takeshima, Yoshihito Kadota, Minako Azuma, Tsuyoshi Fukushima, Natsuki Ogasawara, Tomoki Kawano, Mitsuru Tamura, Jyunichiro Muta, Kiyotaka Saito, Go Takeishi, Asako Mizuguchi, Takashi Watanabe, Hajime Ohta, Kiyotaka Yokogami
-
Preface for Brain Tumor Pathology vol. 39 issue 2 Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-04-08 Hideo Takeshima
-
Implications of immune cells in oncolytic herpes simplex virotherapy for glioma Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-04-06 Yoshihiro Otani, Ji Young Yoo, Toshihiko Shimizu, Kazuhiko Kurozumi, Isao Date, Balveen Kaur
-
Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-04-01 Yukitomo Ishi, Shigeru Yamaguchi, Michinari Okamoto, Ryosuke Sawaya, Shogo Endo, Hiroaki Motegi, Shunsuke Terasaka, Zen-ichi Tanei, Kanako C. Hatanaka, Shinya Tanaka, Miki Fujimura
-
Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-03-29 Dheeraj Chinnam, Kirti Gupta, Tanvi Kiran, Aastha Saraswati, Pravin Salunke, Renu Madan, Narendra Kumar, Bishan Dass Radotra
The 2021 WHO classification stratifies ependymoma (EPN) into nine molecular subgroups according to the anatomic locations which outperforms histological grading. We aimed at molecularly reclassifying 200 EPN using immunohistochemistry (IHC) and sequencing for ZFTA fusions in supratentorial (ST) EPN. Further, we assessed the utility of L1CAM, cyclinD1, and p65 markers in identifying ZFTA fusion. Demographic
-
The 2021 WHO classification of tumors, 5th edition, central nervous system tumors: the 10 basic principles. Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-04-01 Takashi Komori
-
Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-03-21 Kenichiro Asano, Yoji Yamashita, Takahiro Ono, Manabu Natsumeda, Takaaki Beppu, Kenichiro Matsuda, Masahiro Ichikawa, Masayuki Kanamori, Masashi Matsuzaka, Akira Kurose, Toshio Fumoto, Kiyoshi Saito, Yukihiko Sonoda, Kuniaki Ogasawara, Yukihiko Fujii, Hiroaki Shimizu, Hiroki Ohkuma, Chifumi Kitanaka, Takamasa Kayama, Teiji Tominaga
Clinicopathological risk factors for a poor prognosis were investigated in elderly patients with malignant lymphoma of the central nervous system. A total of 82 pathologically confirmed, CD20-positive, diffuse large B-cell lymphoma patients aged 71 years or older who underwent therapeutic intervention in the Tohoku and Niigata area in Japan were retrospectively reviewed. A univariate analysis was performed
-
The oligodendroglial histological features are not independently predictive of patient prognosis in lower-grade gliomas Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-03-15 Eriel Sandika Pareira, Makoto Shibuya, Kentaro Ohara, Yu Nakagawa, Tokunori Kanazawa, Dai Kamamoto, Yasutaka Kato, Eri Arai, Eriko Aimono, Kazunari Yoshida, Hiroshi Nishihara, Yae Kanai, Hikaru Sasaki
The relevance of oligodendroglial histological features to patient prognoses is controversial. 93 LrGGs resected for about 2 decades were re-assessed based on WHO2007 with special interest to pure oligodendroglial diagnosis (oligodendroglioma or anaplastic oligodendroglioma) and presence of CFO features. Those histological features, patients OS, and tumor chromosomal/genetic characteristics were correlated
-
Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-01-31 Hideyuki Arita, Koichi Ichimura
TERT promoter mutations are one of the most common genetic alterations in adult-type diffuse gliomas and show specific patterns compared with other genetic alterations according to glioma subtypes. This mutation has variable impacts on patient outcomes in association with other genetic alterations, including IDH1/2 mutations or histological types. The purpose of this paper is to review the current
-
Emerging glioneuronal and neuronal tumors: case-based review Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-01-20 So Dug Lim, Seong Ik Kim, Jin Woo Park, Jae Kyung Won, Seung-Ki Kim, Ji Hoon Phi, Chun-Kee Chung, Seung-Hong Choi, Hongseok Yun, Sung-Hye Park
Glioneuronal and neuronal tumors (GNTs) are rare heterogeneous central nervous system tumors characterized by slow growth and favorable outcomes, but are often associated with diagnostic difficulties. A thorough analysis of three rare and recently recognized GNTs was performed in the context of clinicopathological features and molecular genetic characterization. The current spinal diffuse leptomeningeal
-
Histopathological predictors of progression-free survival in atypical meningioma: a single-center retrospective cohort and meta-analysis Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-01-15 Min-Sung Kim, Se-Woong Chun, Yun-Sik Dho, Youngbeom Seo, Joo Ho Lee, Jae Kyung Won, Jin Wook Kim, Chul-Kee Park, Sung-Hye Park, Yong Hwy Kim
To determine the prognostic significance of histopathological features included in the diagnostic criteria of atypical meningioma for progression-free survival (PFS). We performed a retrospective cohort study and meta-analysis. Brain invasion, mitotic index, spontaneous necrosis, sheeting, prominent nucleoli, high cellularity, and small cells were the histopathological features of interest. The data
-
A patient with two gliomas with independent oligodendroglioma and glioblastoma biology proved by DNA-methylation profiling: a case report and review of the literature Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-01-11 Theo F. J. Kraus, Christoph Schwartz, Lukas Machegger, Barbara Zellinger, Dorothee Hölzl, Hans U. Schlicker, Johannes Pöppe, Barbara Ladisich, Mathias Spendel, Michael Kral, Karl Sotlar
Here, we report on a patient presenting with two histopathologically distinct gliomas. At the age of 42, the patient underwent initial resection of a right temporal oligodendroglioma IDH mutated 1p/19q co-deleted WHO Grade II followed by adjuvant radiochemotherapy with temozolomide. 15 months after initial diagnosis, the patient showed right hemispheric tumor progression and an additional new left
-
Role of proliferative marker index and KBTBD4 mutation in the pathological diagnosis of pineal parenchymal tumors Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-01-09 Eita Uchida, Atsushi Sasaki, Mitsuaki Shirahata, Tomonari Suzuki, Jun-ichi Adachi, Kazuhiko Mishima, Masanori Yasuda, Takamitsu Fujimaki, Koichi Ichimura, Ryo Nishikawa
Pineal parenchymal tumors (PPTs) are clinically rare and a biopsy is often required for a definitive diagnosis. To improve the accuracy of histological assessment of PPTs, we examined the proliferative capacity of PPT cells and investigated DICER1 expression and KBTBD4 mutations. This study included 19 cases of PPTs [3 pineocytomas (PCs), 10 PPTs of intermediate differentiation (PPTID), and 6 pineoblastomas
-
Timing of H3K27me3 loss in secondary anaplastic meningiomas. Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-01-06 Serena Ammendola,Valeria Barresi
-
Correction to: Epithelioid inflammatory myofibroblastic sarcoma with VCL–ALK fusion of central nervous system: case report and brief review of the literature Brain Tumor Pathol. (IF 3.3) Pub Date : 2022-01-01 Shefali Chopra,Nolan Maloney,Wei Lien Wang
-
Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas Brain Tumor Pathol. (IF 3.3) Pub Date : 2021-11-26 Nishikawa, Tomohide, Watanabe, Reiko, Kitano, Yotaro, Yamamichi, Akane, Motomura, Kazuya, Ohka, Fumiharu, Aoki, Kosuke, Hirano, Masaki, Kato, Akira, Yamaguchi, Junya, Maeda, Sachi, Kibe, Yuji, Saito, Ryuta, Wakabayashi, Toshihiko, Kato, Yukinari, Sato, Shuta, Ogino, Tomoyoshi, Natsume, Atsushi, Ito, Ichiro
Since the World Health Organization 2016 classification (2016 WHO), genetic status has been incorporated into the diagnosis of Grade 2/3 gliomas (lower-grade gliomas). Therefore, immunohistochemistry (IHC) of IDH1-R132H, ATRX, and p53 have been used in place of genetic status. We report the associations between histological findings, IHC, and genetic status. We performed IHC of IDH1-R132H, ATRX, and
-
Molecular subtyping of ependymoma and prognostic impact of Ki-67 Brain Tumor Pathol. (IF 3.3) Pub Date : 2021-11-23 Lim, Ka Young, Lee, Kwanghoon, Shim, Yumi, Park, Jin Woo, Kim, Hyunhee, Kang, Jeongwan, Won, Jae Kyung, Kim, Seung-Ki, Phi, Ji Hoon, Park, Chul-Kee, Chung, Chun-Kee, Yun, Hongseok, Park, Sung-Hye
Although ependymomas (EPNs) have similar histopathology, they are heterogeneous tumors with diverse immunophenotypes, genetics, epigenetics, and different clinical behavior according to anatomical locations. We reclassified 141 primary EPNs from a single institute with immunohistochemistry (IHC) and next-generation sequencing (NGS). Supratentorial (ST), posterior fossa (PF), and spinal (SP) EPNs comprised
-
Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement Brain Tumor Pathol. (IF 3.3) Pub Date : 2021-11-18 Magaki, Shino, Satyadev, Radha, Chen, Zesheng, Yung, Kathryn S., Vinters, Harry V., Kinney, Marsha C., Said, Jonathan W.
Anaplastic large cell lymphomas (ALCL) are mature T-cell neoplasms, approximately half of which harbor rearrangements of the ALK gene that confer a good prognosis. Recent studies have demonstrated that a significant proportion of ALK-negative ALCLs demonstrate rearrangements of the IRF4/DUSP22 locus that also are typically associated with a favorable prognosis. ALCL with primary involvement of the